Cencora, Inc. $COR Shares Purchased by AE Wealth Management LLC

AE Wealth Management LLC increased its position in Cencora, Inc. (NYSE:COR) by 6.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,792 shares of the company’s stock after acquiring an additional 1,283 shares during the period. AE Wealth Management LLC’s holdings in Cencora were worth $6,234,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Invesco Ltd. raised its position in shares of Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after purchasing an additional 1,364,433 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Cencora by 4,459.6% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock valued at $277,321,000 after buying an additional 975,362 shares during the period. Price T Rowe Associates Inc. MD increased its position in Cencora by 8.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after purchasing an additional 787,858 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Cencora during the 1st quarter worth $181,284,000. Finally, Caisse DE Depot ET Placement DU Quebec raised its holdings in shares of Cencora by 144.4% in the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 743,072 shares of the company’s stock worth $206,641,000 after purchasing an additional 439,008 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $360.56 on Monday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. Cencora, Inc. has a one year low of $223.92 and a one year high of $364.36. The company has a market capitalization of $69.90 billion, a PE ratio of 37.09, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. The stock has a fifty day moving average of $314.27 and a 200-day moving average of $299.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be issued a dividend of $0.60 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Friday, November 14th. Cencora’s dividend payout ratio is presently 30.19%.

Analysts Set New Price Targets

Several brokerages recently issued reports on COR. Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a report on Saturday. Wells Fargo & Company boosted their target price on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 13th. Evercore ISI set a $400.00 price objective on Cencora and gave the stock an “outperform” rating in a research note on Thursday. UBS Group raised their target price on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday. Finally, Robert W. Baird raised their target price on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research report on Thursday. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $351.50.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 41,544 shares of company stock worth $12,230,941 in the last quarter. 10.80% of the stock is owned by corporate insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.